- Conditions
- Metastatic Cancer, Prostate Cancer
- Interventions
- atrasentan hydrochloride, docetaxel, prednisone, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,038 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 554
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 68
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Cancer
- Interventions
- Cabozantinib, Nivolumab
- Drug
- Lead sponsor
- Rana McKay, MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- La Jolla, California • Chicago, Illinois • Dallas, Texas + 1 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Erdafitinib
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Carcinoma Metastatic to the Bone
- Interventions
- Enzalutamide, Radium ra 223 dichloride
- Drug · Radiation
- Lead sponsor
- Carolina Research Professionals, LLC
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Towson, Maryland • Syracuse, New York • Myrtle Beach, South Carolina + 1 more
- Conditions
- Prostate Cancer
- Interventions
- Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone
- Drug
- Lead sponsor
- Carolina Research Professionals, LLC
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer
- Interventions
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Adenocarcinoma
- Interventions
- cabozantinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Bone marrow transplantation, Cytoxan, testosterone cypionate
- Procedure · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7, Metastatic Malignant Neoplasm in the Bone
- Interventions
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Sirolimus
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer, Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)
- Interventions
- Tasquinimod, Radium 223
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
- Interventions
- Enzalutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Farmington Hills, Michigan • New Brunswick, New Jersey + 1 more
- Conditions
- Prostate Cancer
- Interventions
- Radium-223, Sipuleucel-T
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • New Orleans, Louisiana + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging
- Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • New York, New York • Madison, Wisconsin
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- enzalutamide, abiraterone acetate, prednisone
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
- Interventions
- Ipilimumab, Nivolumab, Enzalutamide
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Adenocarcinoma of the Prostate, Castration-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cancer, Carcinoma, Castrate-Resistant Prostate Cancer, Prostate Cancer, Tumors
- Interventions
- Denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Anaheim, California • Laguna Hills, California + 23 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Radium-223 dichloride (BAY88-8223)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more
- Conditions
- Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 24 more
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Cabozantinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
- Interventions
- Enzalutamide
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 2
- States / cities
- San Francisco, California • Portland, Oregon
- Conditions
- Metastatic Progressive Castration-resistant Prostate Cancer
- Interventions
- Enzalutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Prostate Small Cell Carcinoma
- Interventions
- Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Houston, Texas